Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced that three company-sponsored abstracts will be presented at the 2015 American Thoracic Society (ATS) International Conference in Denver, Colorado on May 15-19, 2015.

Data to be presented include a Phase III study examining the functionality, reliability, accuracy and overall patient satisfaction of ProAir® RespiClick (albuterol sulfate) inhalation powder, which gained approval from theU.S. Food and Drug Administration (FDA) in March 2015. ProAir® RespiClick is now available by prescription and is indicated for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm in patients 12 years of age and older.

Additional Phase III data to be presented include a late-breaking abstract highlighting an interim analysis of the long-term safety and efficacy of Teva’s investigational anti-IL-5 therapy, reslizumab, in patients with asthma and elevated blood eosinophils. A third abstract to be presented includes data from a dose-ranging study of fluticasone propionate multi-dose, dry-powder inhaler (MDPI) in adolescent and adult patients with asthma.

“The 2015 ATS International Conference provides Teva with a scientific platform to showcase findings for three of our new or investigational asthma therapies,” said Tushar Shah, MD, Senior Vice President, Teva Global Respiratory Research and Development. “These findings underscore the exciting progress being made to further expand our respiratory portfolio through the development of new treatment options that address unmet needs of patients.”

The following data will be presented during poster sessions on Tuesday, May 19, 2015:

ProAir® RespiClick (albuterol sulfate) Inhalation Powder

  • # P308: A Prospective, Open-Label Study of a New Albuterol Multidose Dry Powder Inhaler With Integrated Dose Counter
    • This abstract will be presented from 11:30 AM to 1:15 PM in Area C, Hall A-B at the Colorado Convention Center.

Fluticasone Propionate MDPI

  • #P258: Dose-Ranging Study of a Fluticasone Propionate Multidose Dry Powder Inhaler in Adolescents and Adults With Asthma Uncontrolled by Noncorticosteroid Asthma Medications
    • This abstract will be presented from 11:30 AM to 1:15 PM in Area C, Hall A-B at the Colorado Convention Center.


  • #1025: Long-Term Safety and Efficacy of Reslizumab in Patients with Inadequately Controlled, Moderate-to-Severe Asthma and Elevated Blood Eosinophil Counts: An Open-Label Extension Study.
    • This late-breaking abstract will be presented from 2:15 to 4:15 PM in the Capitol Ballroom at the Hyatt Regency Denver at the Colorado Convention Center. (Original Source)

Shares of Teva closed yesterday at $61.22 . TEVA has a 1-year high of $68.75 and a 1-year low of $47.36. The stock’s 50-day moving average is $63 and its 200-day moving average is $58.65.

On the ratings front, Tevahas been the subject of a number of recent research reports. In a report issued on April 30, Oppenheimer analyst Akiva Felt maintained a Buy rating on TEVA, with a price target of $77, which represents a potential upside of 25.8% from where the stock is currently trading. Separately, on April 29, Standpoint Research’s Ronnie Moas upgraded the stock to Buy and has a price target of $80.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Akiva Felt and Ronnie Moas have a total average return of 32.8% and 9.5% respectively. Felt has a success rate of 68.8% and is ranked #25 out of 3602 analysts, while Moas has a success rate of 74.4% and is ranked #10.

The street is mostly Bullish on TEVA stock. Out of 8 analysts who cover the stock, 7 suggest a Buy rating and one recommend to Hold the stock. The 12-month average price target assigned to the stock is $71.88, which implies an upside of 17.4% from current levels.

Teva Pharmaceutical Industries Ltd develops, produces and markets generic, branded & OTC medicines. Some of its products are Copaxone, Azilect & Provigil.